[go: up one dir, main page]

GB202309922D0 - Antisense treatment - Google Patents

Antisense treatment

Info

Publication number
GB202309922D0
GB202309922D0 GBGB2309922.9A GB202309922A GB202309922D0 GB 202309922 D0 GB202309922 D0 GB 202309922D0 GB 202309922 A GB202309922 A GB 202309922A GB 202309922 D0 GB202309922 D0 GB 202309922D0
Authority
GB
United Kingdom
Prior art keywords
antisense treatment
antisense
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2309922.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Priority to GBGB2309922.9A priority Critical patent/GB202309922D0/en
Publication of GB202309922D0 publication Critical patent/GB202309922D0/en
Priority to PCT/GB2024/051634 priority patent/WO2025003660A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2309922.9A 2023-06-29 2023-06-29 Antisense treatment Ceased GB202309922D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2309922.9A GB202309922D0 (en) 2023-06-29 2023-06-29 Antisense treatment
PCT/GB2024/051634 WO2025003660A2 (en) 2023-06-29 2024-06-26 Antisense treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2309922.9A GB202309922D0 (en) 2023-06-29 2023-06-29 Antisense treatment

Publications (1)

Publication Number Publication Date
GB202309922D0 true GB202309922D0 (en) 2023-08-16

Family

ID=87557004

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2309922.9A Ceased GB202309922D0 (en) 2023-06-29 2023-06-29 Antisense treatment

Country Status (2)

Country Link
GB (1) GB202309922D0 (en)
WO (1) WO2025003660A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205615A1 (en) * 2015-06-17 2016-12-22 The Johns Hopkins University Tdp-43 in degenerative disease
WO2022018155A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Lna oligonucleotides for splice modulation of stmn2
EP4320236A1 (en) * 2021-04-06 2024-02-14 Maze Therapeutics, Inc. Compositions and methods for treating tdp-43 proteinopathy

Also Published As

Publication number Publication date
WO2025003660A3 (en) 2025-03-06
WO2025003660A2 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
IL315403A (en) Mirdametinib treatment
GB202309922D0 (en) Antisense treatment
GB202016058D0 (en) Therapeautic treatment
GB202006236D0 (en) New treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202319954D0 (en) Treatment
GB202319658D0 (en) Treatment
GB202319443D0 (en) Treatment
GB202318845D0 (en) Treatment
GB202311007D0 (en) Treatment
GB202304853D0 (en) Treatment
GB202218460D0 (en) Treatment
GB202304716D0 (en) New treatment
GB202214206D0 (en) Treatment
GB202212125D0 (en) Treatment
GB202210430D0 (en) New treatment
GB202204288D0 (en) Treatment
GB202204070D0 (en) Treatment
GB202206219D0 (en) New treatment
GB202201069D0 (en) Treatment
GB202212566D0 (en) Combination treatment
GB202500384D0 (en) New treatment
GB202415544D0 (en) New treatment
GB202507490D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)